Clouds of Care de-risks CNS clinical development by identifying and validating clinically relevant endpoints through multimodal data aggregation and analysis. Their platform connects to a network of Digital Health Technologies to generate scientifically validated insights, improving the probability of success for CNS drug development.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing central nervous system (CNS) therapies faces challenges in identifying and validating meaningful clinical endpoints, which can lead to increased development risk and reduced success probability. Traditional methods often lack the precision and multimodal data integration required to capture the nuanced effects of CNS-acting compounds.
Solution
Clouds of Care offers a platform that de-risks CNS clinical development by identifying clinically relevant endpoints through the aggregation and analysis of multimodal data. The platform connects to a curated network of Digital Health Technology (DHT) solutions to acquire and process data, generating scientifically validated insights. This approach enhances the probability of success by enabling the adoption of hypothesis-driven and future-proof clinical endpoints, starting with electrophysiology. The company provides advisory services for endpoint selection, DHT partner identification, and data acquisition, aggregation, and analysis.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies engaged in CNS drug development, particularly those seeking to improve the precision and success rates of their clinical trials.
Features
- Platform for acquiring, aggregating, and analyzing multimodal data from a curated network of Digital Health Technology (DHT) solutions.
- Services include multimodal endpoints advisory, DHT partner selection, and data acquisition, aggregation, and analysis.
- Focus on identifying and validating meaningful CNS endpoints, with an initial emphasis on electrophysiology.
- Utilizes a vendor-neutral, data-driven approach to improve Return on Investment (ROI) in CNS drug development.
- Provides interpretation of data insights and translation into actionable clinical development strategies.
- Case studies demonstrate the application of standardized Pharmaco-EEG in clinical development for evaluating CNS-active compounds.